Table 1 In vitro experimental data of radiosensitization effects
From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Authors | CDK4/6 inhibitor | Human cell line | Efficacy with radiotherapy |
|---|---|---|---|
Whiteway et al. [41] | Palbociclib | Medulloblastoma (Daoy) (ONS-76) | SF2 a ↓ SER10 b 1.6, SER50 c 1.5 SER10 2.3, SER50 2.3 |
Hashizume et al. [42] | Palbociclib | Intracranial ATRT d (BT12) (BT16) | DEF e 1.16–1.60 DEF 1.18–1.70 |
Whittaker et al. [43] | Palbociclib | Glioblastoma (GBM-L1, HW1, RN1, BAH1) | Colony numbers drop to zero |
Naz et al. [44] | Abemaciclib | NSCLC (A549, H460, H820, H1975) | DMF f 1.30–1.71 |
Tao et al. [30] | Palbociclib and Trametinib | NSCLC (A549, H460) | Cell survival fraction ↓ Apoptosis ↑ |
Huang et al. [45] | Palbociclib | HCC (Hep3B, Huh7) CCA g (HuCCT1) | Tumor sphere numbers ↓ Colony numbers ↓ |
Xie et al. [46] | Palbociclib | NPC (CNE-1) (CNE-2) | SF2 ↓ SER 1.118–1.475 SER 1.10–1.20 |
Gottgens et al. [47] | Palbociclib | HNSCC (UT-SCC-24A) | SER 1.36–1.60 |
Tai et al. [48] | Ribociclib | HNSCC (OML1, OML1-R) | Colony numbers ↓ Cell viability ↓ |
Fernández-Aroca et al. [49] | Palbociclib | Breast cancer (MCF-7) Lung cancer (A549) Colorectal cancer (HCT116) | Cell survival fraction ↓ |
Li et al. [50] | Ribociclib and CA3 | EAC h (Flo-1 XTR) | Colony numbers ↓ |